Figure 2.

Kaplan-Meier recurrence rates in patients receiving intravesical bacillus Calmette-Guérin (BCG) and interferon (IFN) characterized by whether they never received BCG (BCG-N) or had tumor recurrence after prior BCG (BCG-F). Reprinted from Urologic Oncology: Seminars and Original Investigations, Volume 24, Joudi FN et al, “Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer,” pages 344–348, Copyright 2006, with permission from Elsevier.